This feature highlights changes in clinical trial organizations’ personnel.

Adicet Bio

Blake Aftab has been named vice president of research at Adicet Bio. Previously, Aftab was vice president of preclinical and translational science at Atara Biotherapeutics.

Candel Therapeutics

Chris Matheny has been appointed vice president and development leader of Candel Therapeutics. Matheny was most recently asset development leader at GlaxoSmithKline.

Cogent Biosciences

Cogent Biosciences has named John Robinson the company’s new chief scientific officer. Robinson was most recently vice president of medicinal chemistry at Pfizer.

Eli Lilly

Diogo Rau has been named Eli Lilly’s newest senior vice president and chief information and digital officer. Most recently, Rau was a senior director at Apple.

F2G

Francesco Maria Lavino has been appointed CEO of clinical-stage biopharmaceutical company F2G. Most recently, Lavino was acting chief commercial officer at Sesen Bio.

FDA

The FDA has named Patrizia Cavazzoni as its permanent director of the Center for Drug Evaluation and Research (CDER). Cavazzoni most recently served as CDER’s deputy director for operations.

Frequency Therapeutics

Jeffery Lichtenhan has joined Frequency Therapeutics to lead the company’s clinical development programs. Most recently, Lichtenhan was assistant professor of otolaryngology and audiology and communication sciences at Washington University School of Medicine.

Gemini Therapeutics

Samuel Barone has been named the chief medical officer of Gemini Therapeutics. Prior to joining Gemini, Barone was the co-founder, manager and chief medical officer of Halodine.

Jounce Therapeutics

Dmitri Wiederschain has been appointed chief scientific officer of Jounce Therapeutics. Formerly, Wiederschain was the vice president and global head of immuno-oncology research at Sanofi.

Kyverna Therapeutics

Kyverna Therapeutics has found its newest chief medical officer in James Chung, Amgen’s former executive medical director.

Lung Therapeutics

Cory Hogaboam has been named chief scientific officer of Lung Therapeutics. Hogaboam currently serves as professor of medicine at Cedars Sinai Medical Center.

Mission Bio

Yan Zhang has taken the reins of Mission Bio as the company’s new CEO. Zhang was most recently the vice president and general manager at Thermo Fisher Scientific.

Novavax

Novavax has appointed Troy Morgan to senior vice president and chief compliance officer. Morgan was most recently chief compliance officer at EMD Serono.

Prothena Corporation

Prothena Corporation has appointed Hideki Garren to the role of chief medical officer. Garren is the former vice president and global head of the neuroimmunology franchise at Roche.

Pyramid Biosciences

Pyramid Biosciences has named Brian Lestini the company’s new chief medical officer. Lestini was most recently vice president of oncology development at Bristol Myers Squibb.

Skyhawk Therapeutics

Elliot Ehrich has been named president of Skyhawk Therapeutics. Recently, Ehrich served as executive vice president of R&D and chief medical officer at Alkermes. Another new hire at Skyhawk is Graeme Smith, who has been tapped to serve as the company’s senior vice president of nonclinical development.

Tollys

Biopharmaceutical company Tollys has appointed Amina Zinaï to head of clinical development. Zinaï was formerly the project director at Servier.

Tyra Biosciences

Tyra Biosciences has brought onboard Hiroomi Tada to serve as chief medical officer. Tada was most recently the chief medical officer of Notable Labs.

Wugen

Daniel Kemp, former Takeda vice president, has been appointed CEO of clinical-stage biotech company Wugen.

Xilio Therapeutics

Xilio Therapeutics has promoted Rónán O’Hagan from senior vice president of research and translational sciences to chief scientific officer. O’Hagan led Merck’s oncology discovery program prior to joining Xilio in 2018.

XNK Therapeutics

Johan Aschan, former global clinical lead at Oncopeptides, has been named chief medical officer of XNK Therapeutics.

Yumanity Therapeutics

Ajay Verma has been appointed to executive vice president and head of R&D at Yumanity Therapeutics. Most recently, Verma was executive vice president of research and experimental medicine at Codiak Biosciences.